ClinicalTrials.gg
Active, not recruitingNCT05394116OPTIMAUpdated Jul 17, 2026

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 3 interventional study of Garetosmab and Placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 22 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP).

The aim of the study is to see how safe and effective the study drug is in patients with FOP.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Keywords

  • Heterotopic Ossification (HO) Lesions
  • Type I activin A receptor (ACVR1)
  • Optima
  • LUMINA-1
  • Flare-Ups
03

In context

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

This study's enrollment of 63 is above the median of 48 across 16 interventional studies indexed under Myositis Ossificans.

Browse Myositis Ossificans studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Clinical diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) [(based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive Heterotopic Ossification (HO)]
  2. Confirmation of FOP diagnosis with documentation of Type I activin A receptor (ACVR1) FOP causing mutation
  3. FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, or other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of HO lesions (increase in size or number of HO lesions) with/without being associated with flare-up episodes
  4. Willing and able to undergo CT imaging procedures and other procedures as defined in the protocol

Key Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS) score at screening >19
  2. Participant has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
  3. Previous history or diagnosis of cancer
  4. Severely impaired renal function defined as estimated \<30 milliliter per minute (mL/min) (/1.73 m\^2 calculated by the Modification of Diet in Renal Disease equation
  5. Uncontrolled diabetes defined as (HbA1c) >9% at screening
  6. History of poorly controlled hypertension, as defined by:

    1. Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at the screening visit
    2. Systolic blood pressure of 160 mm Hg to 179 mm Hg or diastolic blood pressure of 100 mm Hg to 10\^9 mm Hg at the screening visit, AND a history of end-organ damage (including history of left-ventricular hypertrophy, heart failure, angina, myocardial infarction, stroke, , peripheral arterial disease, end-stage renal disease, and moderate-to-advanced retinopathy
  7. Known history of cerebral vascular malformation
  8. Cardiovascular conditions such as class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia
  9. History of severe respiratory compromise requiring oxygen, respiratory support (eg, bilevel positive airway pressure [biPAP] or continuous positive airway pressure [CPAP]), or a history of aspiration pneumonia requiring hospitalization
  10. Prior use in the past year and concomitant use of bisphosphonates
  11. Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures (eg, collection of blood or tissue samples)
  12. Treatment with another drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer
  13. Pregnant or breastfeeding women
  14. Women of (WOCBP) who are unwilling to practice highly effective , as defined in the protocol
  15. Male patients with WOCBP partners who are not willing to use condoms with WOCBP partners to prevent potential fetal exposure, as defined in the protocol

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    High dose Garetosmab

    Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)

    Drug: Garetosmab

  • Experimental
    Low dose Garetosmab

    Garetosmab is administered by IV administration Q4W

    Drug: Garetosmab

  • Experimental
    Placebo

    Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.

    Drug: Placebo

Interventions

  • Garetosmab is supplied as a liquid drug product and will be administered IV.

    Also known as: REGN2477

  • DrugPlacebo

    Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.

06

What researchers measure

Primary outcomes

  1. Number of new HO lesions

    Time frame: At Week 56

  2. Incidence and severity of treatment-emergent adverse events of special interest (AESIs)

    Time frame: Baseline to Week 56

Secondary outcomes

  1. Number of clinician-assessed flare-ups

    Investigator assess flare-up events according to his/her medical judgment. A FOP flare-up is characterized as episodic, painful inflammatory soft tissue swelling. Week 84 Only for Patients on Extended Treatment

    Time frame: Through Weeks 28, 56 and 84

  2. Occurrence of new HO lesions

    Reported as Yes/No Week 84 Only for Patients on Extended Treatment

    Time frame: At Weeks 28, 56 and 84

  3. Total volume of new HO lesions

    Week 84 Only for Patients on Extended Treatment

    Time frame: At Weeks 28, 56 and 84

  4. Occurrence of patient-reported flare-ups

    Reported as Yes/No

    Time frame: Through Weeks 28 and 56

  5. Number of new HO lesions

    Week 84 Only for Patients on Extended Treatment

    Time frame: At week 28 and 84

  6. Occurrence of clinician-assessed flare-ups

    Reported as Yes/No Week 84 Only for Patients on Extended Treatment

    Time frame: Through Weeks 28, 56 and 84

  7. Number of patient-reported flare-ups

    Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily.

    Time frame: Through Weeks 28 and 56

  8. Change in joint function assessment by physician using cumulative analog joint involvement scale (CAJIS)

    CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30

    Time frame: Baseline to Weeks 28 and 56

  9. Change in pulmonary function as assessed by spirometry

    Forced vital capacity (FVC) and Forced expiratory volume in 1 second (FEV1) and the ratio of FEV1/FVC will be determined by spirometry.

    Time frame: Baseline at Weeks 28 and 56

  10. Change in disease severity as assessed by the Patient Global Impression of Severity (PGIS)

    PGIS is a single item, self-administered questionnaire to assess the patient's global impression of severity

    Time frame: Baseline to Weeks 28 and 56

  11. Change in disease severity as assessed by the Patient's Global Impression of Change (PGIC)

    PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change

    Time frame: At Weeks 28 and 56

  12. Change in disease severity as assessed by the Clinician's Global Impression of Change (CGIC)

    CGIC is a single-item questionnaire to assess the clinician's global impression of change

    Time frame: At Weeks 28 and 56

  13. Concentration of total activin A in serum over time

    Time frame: Through Week 56

  14. Concentration of garetosmab in serum over time

    Time frame: Through Week 56

  15. Incidence of anti-drug antibodies (ADA) to garetosmab over time

    Time frame: Through Week 56

  16. Titer of ADA to garetosmab over time

    Time frame: Through Week 56

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jul 2025, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 27, 2022
StartActual
Nov 21, 2022
Primary completionActual
Jul 17, 2025
CompletionEst.
Feb 27, 2029
Results delay requested
Jul 15, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05394116
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Nov 21, 2022
Primary completion
Jul 17, 2025
Completion
Feb 27, 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion